Heron Therapeutics, Inc. (HRTX)
HRTX moved a median of -0.34% 30 minutes after news, and -0.77% by the close. How HRTX actually reacts to news — the realized, point-in-time move the market made, measured across 247 labeled events over the last three years with zero look-ahead.
HRTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 245 |
| 30-min | -0.34% | 42% | 246 |
| 60-min | 0.00% | 46% | 247 |
| to close | -0.77% | 36% | 242 |
| Middle 50% of HRTX reactions | -1.81% to +0.86% |
|---|---|
| Median reaction (30-min) | -0.34% |
| Measured reactions | 247 |
Half of all Heron Therapeutics, Inc. news events land between -1.81% and +0.86% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How HRTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | +0.09% | 58% | -0.61% |
| Analyst downgrades | 18 | -2.79% | 22% | -4.10% |
| Rating reiterations | 26 | -0.31% | 46% | +0.66% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how HRTX ranks against every other measured name →
That’s how HRTX usually reacts — get an email when it moves on news →Email me when HRTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HRTX's baseline. Nothing else.
Recent HRTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K HERON THERAPEUTICS, INC. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +2.18% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.57% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.41% | — | |
| Form 8-K HERON THERAPEUTICS, INC. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -7.41% | — | |
| Heron Therapeutics Announces Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -7.41% | — | |
| Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 | Press release | GlobeNewswire | +0.00% | -2.30% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.44% | +4.72% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.74% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.41% | |
| U.S. District Court Issues Decision Regarding CINVANTI® Patents | Press release | GlobeNewswire | -8.80% | -34.78% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -8.26% | -12.36% | |
| Form 8-K HERON THERAPEUTICS, INC. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -8.26% | -12.36% | |
| Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance | Press release | GlobeNewswire | -8.26% | -12.36% | |
| Form ARS HERON THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.41% | -0.83% | |
| Form DEF 14A HERON THERAPEUTICS, INC. For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | -0.41% | -0.83% | |
| Form DEFA14A HERON THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.41% | -0.83% | |
| Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 | Press release | GlobeNewswire | +0.71% | +0.83% | |
| Form PRE 14A HERON THERAPEUTICS, INC. For: Apr 20 | SEC filing · Form PRE | SEC EDGAR | -2.86% | -2.86% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | +1.25% | +1.31% | |
| Form 10-K HERON THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.23% | -3.23% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +3.23% | -3.23% | |
| Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results | Press release | GlobeNewswire | +3.23% | -3.23% | |
| Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 | Press release | GlobeNewswire | +0.43% | +2.59% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -0.76% | -6.28% | |
| Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth | Press release | GlobeNewswire | +14.84% | +8.59% | |
| Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) | Press release | GlobeNewswire | -3.54% | +3.15% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.70% | -2.56% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -1.70% | -2.56% | |
| Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress | Press release | GlobeNewswire | -1.70% | -2.56% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Oct 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.87% | |
| Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors | Press release | GlobeNewswire | +0.00% | -0.87% | |
| Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | Press release | GlobeNewswire | -0.39% | -8.46% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | +0.00% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | -3.70% | |
| Form DEF 14A HERON THERAPEUTICS, INC. For: Oct 13 | SEC filing · Form DEF | SEC EDGAR | -0.41% | +6.56% | |
| Form EFFECT HERON THERAPEUTICS, INC. | SEC filing · Form EFFECT | SEC EDGAR | -0.40% | -3.20% | |
| Form PRE 14A HERON THERAPEUTICS, INC. For: Sep 09 | SEC filing · Form PRE | SEC EDGAR | +1.94% | -1.55% | |
| Form S-3 HERON THERAPEUTICS, INC. | SEC filing · Form S-3 | SEC EDGAR | +1.94% | -1.55% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | -3.57% | |
| Form 8-A12B HERON THERAPEUTICS, INC. | SEC filing · Form 8-A12B | SEC EDGAR | +0.00% | -2.92% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.92% | |
| Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value | Press release | PR Newswire | +0.00% | -2.92% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -4.08% | -4.76% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -4.08% | -4.76% | |
| Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.43% | -8.33% | |
| Form 8-K HERON THERAPEUTICS, INC. For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | -2.43% | -8.33% | |
| Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile | Press release | PR Newswire | -2.43% | -8.33% | |
| Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress | Press release | PR Newswire | -2.43% | -8.33% | |
| Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 | Press release | PR Newswire | -2.43% | -8.33% | |
| Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 | Press release | PR Newswire | -1.10% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HRTX section they belong to.
Where else HRTX is measured.
HRTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kala Pharmaceuticals, Inc. (KALA) | 248 | +0.41% | 56% |
| MELINTA THERAPEUTICS INC (MLNT) | 248 | -0.38% | 34% |
| Intra-Cellular Therapies Inc. (ITCI) | 247 | -0.04% | 44% |
| Avadel Pharmaceuticals plc - Ordinary Share (AVDL) | 246 | -0.16% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Heron Therapeutics, Inc.'s median reaction calculated?
Every labeled HRTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 247 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of HRTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HRTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.